Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6130 上亞科技. Please read: https://finlab.finance/en/setup?stock=6130

No install, open FinLab Studio

6130

上亞科技 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 上亞科技 to your watchlist to track signal changes on your next visit.
Valuation 36Quality 8Growth 77Momentum 4Chips 15

Is 上亞科技 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 8th market percentile. Latest quarterly ROE ≈ -2.6%.

  • Valuation is neutral.PE is in the 52th market percentile; within its own history, PE is around the 29th percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -3.5% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 35.7%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral +0.15
BearishNeutralBullish

Institutional rotation, concentration steady — neutral

  • Institutional rotation, concentration steady — neutral
  • 群益金鼎-嘉義 holds 757 lots
  • sellers have 289 lots left, ~475 sessions to clear

Window from 2026-01-17 · Price -42% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 群益金鼎-嘉義 has accumulated 757 lots since the start (sold 0%), still adding.
  • Main distributor 港商野村 peaked at 186 lots, has sold 36%, 119 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders -0.60pp, mid holders -1, retail +0.04pp — little change.
  • Foreign hedge-desk net short Net short -394 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
群益金鼎-嘉義凱基-民權統一-土城兆豐-公益元大-文心興安第一金-嘉義
Distributing
港商野村新加坡商瑞銀華南永昌-麻豆元大-北屯新光-台中台灣企銀-太平
Desks
own scale
康和-台中群益金鼎-大安亞東元大-館前
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 群益金鼎-嘉義 +757
    sold 0%· still adding
  • 凱基-民權 +623
    sold 0%
  • 統一-土城 +583
    sold 5%
  • 兆豐-公益 +149
    sold 1%· still adding
  • 元大-文心興安 +113
    sold 3%· still adding
  • 第一金-嘉義 +99
    sold 21%

Distributing

  • 港商野村 119 left
    sold 36%· paused recently
  • 新加坡商瑞銀 95 left
    sold 40%· ~475 sessions to clear
  • 華南永昌-麻豆 38 left
    sold 43%· ~17 sessions to clear
  • 元大-北屯 19 left
    sold 71%· paused recently
  • 新光-台中 43 left
    sold 28%· paused recently
  • 台灣企銀-太平 27 left
    sold 53%· ~9 sessions to clear

Desks

  • 康和-台中 -1,280
    unclassified
  • 群益金鼎-大安 -470
    unclassified
  • 亞東 -465
    unclassified
  • 元大-館前 -456
    unclassified
Still selling 289 lots ~475 sessions to bottom at most
Recent buy/sell force +592 absorbed / -115 sold buyers slightly ahead
Hedge-desk net short -183 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 35.68%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

80 historical occurrences (since 2007-04-23)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 29.8%, Sample 57, Median -5.21%, Excess -0.21%, Beat mkt rate 31.6%；60-day: Win 26.8%, Sample 56, Median -14.89%, Excess -5.68%, Beat mkt rate 25%；120-day: Win 29.1%, Sample 55, Median -14.92%, Excess -21.04%, Beat mkt rate 20%

120 days after: historical avg -12.23%

20-day +1.22%
60-day -1.82%
120-day -12.23%
20-day
60-day
120-day
Win
29.8%
26.8%
29.1%
Sample
57
56
55
Median
-5.21%
-14.89%
-14.92%
Excess
-0.21%
-5.68%
-21.04%
Beat mkt rate
31.6%
25%
20%

Over 55 occurrences, 120-day forward avg declined 12.23%, lagged the market by 21.04 pts; win rate 29.1%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 You are here0Insufficient data
40-60 0Insufficient data
60-80 84-20.8% -19.3% 0% -42.3%
80-100 34-30.5% -31% 0% -31.3%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 22.64, at the 28.9th percentile of its own history (20-40 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
Insufficient data
(0d)
Insufficient data
(21d)
-24.1%
Win rate 7.2% Excess -22.4%
69d
60-day momentum down
Now
Insufficient data
(0d)
Insufficient data
(18d)
-3.8%
Win rate 53.1% Excess -14.4%
130d

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

13 times historically; 60-day forward avg -10.4%, win rate 30.8%, beating the market by -12.12 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

12 times historically; 60-day forward avg -6.38%, win rate 41.7%, beating the market by -12.76 pts on average.

What does 上亞科技 do? Company profile

生技醫療業 上櫃

Overview

上亞科技為台灣上櫃普通股，統一編號84659035，成立於1994-01-07，2002-03-26上櫃。公司前身曾為基因國際生醫、星寶國際，2023-09-01更名為上亞科技。依2026年可查資料，公司地址為臺北市內湖區行愛路77巷63號6樓，董事長蔡文杰，總經理蔡中和，發言人陳奮賢，股務代理為永豐金證券，簽證會計師事務所為國富浩華聯合會計師事務所。實收資本額約新台幣4.63億元，已發行普通股約4,630萬股。主要股東與董監持股資料可查到星寶電子科技股份有限公司持股約8,000張、合眾投資股份有限公司持股約6,800張；2026年3月後法人董事改派與董事長異動，市場資料顯示新任董事長為蔡文杰，但亦有媒體報導經營權爭議，應以公開資訊觀測站最新公告為準。2026年第一季營收約3,933.5萬元、歸屬母公司業主淨損約1,356.7萬元、EPS約-0.31元；2025全年合併虧損約7,631萬元、EPS約-1.72元；2026年5月累計營收約7,118.3萬元、年增約4.69%。

Business

公司已由早期無線通訊IC與醫美/生技通路轉型為多業務組合，官方網站描述目前主要有學名藥與太陽能發電兩大業務，近年另新增光學鍍膜，第三方產業資料並揭露仍有電源IC/系統服務相關營收。學名藥業務以代理或進口國內外學名藥、西藥買賣為主，適應症涵蓋神經系統、抗腫瘤、降血糖、心血管、呼吸道、性功能障礙、止痛抗發炎、肝炎等用藥，通路包含醫學中心、公立醫院、財團法人醫院、診所、藥局，並曾取得國防部國軍藥品聯標案與台中榮民總醫院標案。太陽能售電業務係投資太陽能電場，官方資料稱已有12座運營中的發電場，電力銷售予台灣電力公司，2022年收購太陽能案場公司後總裝置容量接近5MW。電源IC/系統服務業務應用於車用、小家電、低軌衛星、手機/平板充電晶片、Type-C擴充、工控、TV、PC/NB、智能風扇控制與衛星傳收高頻製程整合等。光學鍍膜業務聚焦感測晶片晶圓級光學鍍膜加工，透過濾除400至800nm可見光雜訊以提升光學檢測晶片訊號品質，目標應用包含智慧醫療與穿戴式裝置。可查2024營收結構約為積體電路設計43.4%、西藥38.1%、電力14.4%；另MoneyDJ揭露2024營收地區約內銷56%、外銷44%。2025以後營收結構未查得完整官方分項，需待年報或公開資訊觀測站更新確認。

Outlook 2025–2028

2025至2028年主要觀察三條轉型軸線。第一，光學鍍膜是最具題材性的新增成長動能；2025年公司與台亞半導體集團策略夥伴聯合法說及媒體報導指出，第一條光學鍍膜產線通過歐美客戶驗證，月產能約2,800片5吋晶圓鍍膜，並開發新一代技術，目標達每月1萬片5吋晶圓鍍膜；後續若穿戴式、智慧醫療感測晶片需求放量且客戶認證穩定，2026至2028年有機會提升營收規模與毛利結構，但量產良率、客戶集中度、認證時程與價格壓力是不確定因素。第二，學名藥業務具醫療剛性需求與標案機會，受惠高齡化、健保用藥需求與醫院通路延伸，但同時面臨藥價調整、標案價格競爭、供應商交期與法規審查風險。第三，太陽能售電具長約現金流與綠能政策支撐，但裝置容量目前不大，成長取決於新增案場取得、融資成本、併網條件、維運效率與躉購/售電價格。財務面上，公司2023至2026年第一季仍多處虧損狀態，轉型業務尚未明確反映為穩定獲利；2026年亦有私募普通股案與經營權異動訊息，資本結構、治理穩定性、策略延續性與現金流壓力是2025至2028年需持續追蹤的關鍵風險。

Supply Chain

Upstream
  • Hetero Labs 印度學名藥與原料藥/成品藥供應商之一，非台股掛牌；MoneyDJ列為上亞學名藥採購供應商。
  • MSN Laboratories 印度學名藥與原料藥/成品藥供應商之一，非台股掛牌；MoneyDJ列為上亞學名藥採購供應商。
  • 晶圓、導線架與封測供應鏈 電源IC業務主要原料包含晶圓與導線架；未查得公司公開揭露特定台股供應商名稱。
  • 蒸鍍材與光學鍍膜設備/耗材供應商 光學鍍膜主要原料包含蒸鍍材、離子源壓力板等；未查得公司公開揭露特定供應商名稱。
Downstream
  • 台灣電力公司 太陽能發電售電對象；台電為國營事業，非台股上市櫃公司。
  • 醫學中心、公立醫院、財團法人醫院、診所與藥局 學名藥主要銷售通路與終端醫療客戶；多數非上市櫃或未逐一揭露。
  • 台亞半導體 2340 光學鍍膜與感測晶片策略供應鏈關係；媒體報導上亞光學鍍膜事業處為台亞供應鏈策略夥伴的重要環節。
  • 星亞視覺 7753 與上亞、台亞、晉弘、和亞智慧、台北醫學大學共同參與高精度非侵入式連續血糖檢測穿戴裝置技術開發計畫。
  • 晉弘科技 6796 與上亞、台亞、星亞視覺等共同參與經濟部A+企業創新研發淬鍊計畫，方向為非侵入式連續血糖檢測穿戴裝置。
  • 歐美穿戴式/智慧醫療客戶 媒體報導光學鍍膜產線經歐美客戶驗證，且新一代技術獲穿戴式裝置國際品牌採用；公司未公開特定客戶名稱。

Competitors

  • 佳醫 4104 醫療通路、醫藥聯合採購與醫療服務相關同業；與上亞學名藥通路業務部分重疊。
  • 盛弘 8403 醫療服務、醫藥通路與管理服務相關同業；MoneyDJ列為國內醫藥聯合採購業者之一。
  • 偉詮電 2436 電源管理IC同業，與上亞電源IC/系統服務業務具競爭參照。
  • 虹冠電 3257 電源管理IC同業。
  • 點晶 3288 IC設計同業，StockFeel列為上亞電源管理IC競爭對手。
  • 通嘉 3588 電源管理IC同業。
  • 茂達 6138 電源管理IC與類比IC同業。
  • 矽力*-KY 6415 電源管理IC同業，屬台股掛牌KY公司。
  • 統新 6426 光學鍍膜與濾光片相關台股公司，可作為上亞光學鍍膜業務的同業參照。
  • 泓德能源 6873 再生能源開發與售電相關公司，可作為太陽能售電業務同業參照；規模與商業模式不完全相同。
Sources（19）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.